1. Home
  2. GHC vs TVTX Comparison

GHC vs TVTX Comparison

Compare GHC & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Graham Holdings Company

GHC

Graham Holdings Company

HOLD

Current Price

$1,182.66

Market Cap

5.1B

Sector

Real Estate

ML Signal

HOLD

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$56.93

Market Cap

5.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GHC
TVTX
Founded
1877
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.3B
IPO Year
1994
2013

Fundamental Metrics

Financial Performance
Metric
GHC
TVTX
Price
$1,182.66
$56.93
Analyst Decision
Strong Buy
Analyst Count
0
13
Target Price
N/A
$40.62
AVG Volume (30 Days)
17.6K
1.8M
Earning Date
05-12-2026
05-04-2026
Dividend Yield
0.65%
N/A
EPS Growth
N/A
92.89
EPS
66.47
N/A
Revenue
$2,932,099,000.00
N/A
Revenue This Year
$7.73
$44.76
Revenue Next Year
$4.37
$35.51
P/E Ratio
$17.65
N/A
Revenue Growth
N/A
N/A
52 Week Low
$882.21
$15.03
52 Week High
$1,224.76
$60.10

Technical Indicators

Market Signals
Indicator
GHC
TVTX
Relative Strength Index (RSI) 57.95 61.02
Support Level $1,080.80 $54.87
Resistance Level $1,197.19 $60.10
Average True Range (ATR) 34.90 2.20
MACD 0.91 -0.55
Stochastic Oscillator 74.16 48.94

Price Performance

Historical Comparison
GHC
TVTX

About GHC Graham Holdings Company

Graham Holdings Company is a diversified holding company with operations spanning educational services, television broadcasting, healthcare, manufacturing, automotive dealerships, and other businesses. The Company's education activities are conducted through Kaplan, whose services include academic preparation programs for international students, English-language programs, exam preparation, and career and academic advisement. These services are provided to students, schools, and colleges, both domestically and outside the United States. It operates through seven reportable segments: Kaplan International, Kaplan Higher Education, Kaplan Supplemental Education, Television Broadcasting, CSI, Manufacturing and Automotive, with key revenue coming from the Education and Automotive segments.

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Share on Social Networks: